Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer

Author： Troiani Teresa   Martinelli Erika   Orditura Michele   De Vita Ferdinando   Ciardiello Fortunato   Morgillo Floriana  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.7, 2012-07, pp. : 949-959

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2713-2719

Bentham Science Publishers

Access to resources Recommend Favorite

Bevacizumab: Anti-VEGF Monoclonal Antibody, Avastin, Rhumab-VEGF

By  

Drugs in R&D, Vol. 3, Iss. 1, 2002-01 ,pp. : 28-30

Adis International

Access to resources Recommend Favorite

Anti-VEGF Strategies - from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2680-2701

Bentham Science Publishers

Access to resources Recommend Favorite

Resistance to Anti-VEGF Agents

By  

Current Pharmaceutical Design, Vol. 10, Iss. 1, 2004-01 ,pp. : 51-64

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

By Tomao Federica   Papa Anselmo   Rossi Luigi   Caruso Davide   Zoratto Federica   Benedetti Panici Pierluigi   Tomao Silverio  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 37-53

Informa Healthcare

Access to resources Recommend Favorite